FDA Clearance Tracker · P960007-S017
TRANSCYTE
Last checked: Nov 20, 2026Latest source record: Jun 28, 2004 (this decision)Source: openFDAMethods & limitations
Decided
Jun 28, 2004
Approved
Time to decision
676 days
Received Aug 22, 2002. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P960007-S017
- Device name
- TRANSCYTE
- Applicant
- Shire Regenerative Medicine
- Applicant location
- San Diego, CA
- Received
- Aug 22, 2002
- Decided
- Jun 28, 2004
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P960007
Device type
- Device type
- Dressing, wound and burn, interactive (MGR)
- Device class
- Class III
- Specialty
- General & Plastic SurgeryWound Care
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE TERMINATION OF THE POST-APPROVAL STUDY PROTOCOL ENTITLE: "A RANDOMIZED, CONTROLLED WITHIN-PATIENT-PAIRED STUDY TO COMPARE THE EFFECTIVENESS OF TRANSCYTE AND BIOBRANE IN THE TREATMENT OF MID-DERMAL TO INDETERMINATE DEPTH BURN WOUNDS."
Source documents
Other decisions for Shire Regenerative Medicine
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.